These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30641166)

  • 1. An observational, multicentre study on different insulin glargine U100 titration algorithms used in patients with type 2 diabetes in daily medical practice in Adriatic countries: The ADRESA study.
    Krnić M; Marolt I; Skelin M; Grulović N; Rahelić D
    Diabetes Res Clin Pract; 2019 Apr; 150():144-149. PubMed ID: 30641166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
    Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
    Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
    Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.
    Hunt B; Mocarski M; Valentine WJ; Langer J
    Adv Ther; 2017 Apr; 34(4):954-965. PubMed ID: 28281218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin Glargine U100 Improved Glycemic Control and Reduced Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3 and 4.
    Betônico CC; Titan SMO; Lira A; Pelaes TS; Correa-Giannella MLC; Nery M; Queiroz M
    Clin Ther; 2019 Oct; 41(10):2008-2020.e3. PubMed ID: 31383366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS).
    Misra A; Patel M; Agarwal P; Lodha S; Tandon N; Magdum M; Yajnik C; Ghosh R; Walekar A
    Diabetes Technol Ther; 2019 Nov; 21(11):656-664. PubMed ID: 31335198
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia.
    Goldenberg RM; Aroda VR; Billings LK; Christiansen ASL; Meller Donatsky A; Parvaresh Rizi E; Podgorski G; Raslova K; Klonoff DC; Bergenstal RM
    Diabetes Obes Metab; 2021 Nov; 23(11):2572-2581. PubMed ID: 34322967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Optimised glycaemic control and dose titration with insulin glargine (Lantus) by general practitioners in Switzerland: results of the OPTI-LAN Postmarketing Study].
    Spirk D; Lareida J; Scheidegger K; Diem P
    Praxis (Bern 1994); 2009 Mar; 98(6):315-20. PubMed ID: 19291638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
    Davies M; Evans R; Storms F; Gomis R; Khunti K
    Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study.
    Garg SK; Admane K; Freemantle N; Odawara M; Pan CY; Misra A; Jarek-Martynowa IR; Abbas-Raza S; Mirasol RC; Perfetti R
    Endocr Pract; 2015 Feb; 21(2):143-57. PubMed ID: 25297660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study.
    Zhang B; Zhao J; Yang W;
    Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27667797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
    Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study.
    Duque N; Artime E; Romera I; Lebrec J; Díaz S; Rubio M; Sicras-Mainar A; Carretero-Anibarro E; Mundet X; Gorgojo-Martínez JJ; Reviriego J
    Adv Ther; 2021 Jul; 38(7):3857-3871. PubMed ID: 34052987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience after switching from insulin glargine U100 to glargine U300 in patients with type 1 diabetes mellitus. A study after one year of treatment in real life.
    Pujante Alarcón P; Rodríguez Escobedo R; García Urruzola F; Ares J; Manjón L; Sanchez Ragnarson C; Cacho L; Delgado E; Menéndez Torre EL
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Apr; 66(4):210-216. PubMed ID: 30559088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of three algorithms for initiation and titration of insulin glargine in insulin-naive patients with type 2 diabetes mellitus.
    Dailey G; Aurand L; Stewart J; Ameer B; Zhou R
    J Diabetes; 2014 Mar; 6(2):176-83. PubMed ID: 23931125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL.
    Philis-Tsimikas A; Lane W; Pedersen-Bjergaard U; Wysham C; Bardtrum L; Harring S; Heller S
    Diabetes Obes Metab; 2020 May; 22(5):779-787. PubMed ID: 31903697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
    Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
    J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Trial of Long-Acting Insulin Glargine Titration Web Tool (LTHome) Versus Enhanced Usual Therapy of Glargine Titration (INNOVATE Trial).
    Bajaj HS; Venn K; Ye C; Aronson R
    Diabetes Technol Ther; 2016 Oct; 18(10):610-615. PubMed ID: 27652718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.
    Davies M; Lavalle-González F; Storms F; Gomis R;
    Diabetes Obes Metab; 2008 May; 10(5):387-99. PubMed ID: 18355327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender-based differences in glycaemic control and hypoglycaemia prevalence in patients with type 2 diabetes: results from patient-level pooled data of six randomized controlled trials.
    Kautzky-Willer A; Kosi L; Lin J; Mihaljevic R
    Diabetes Obes Metab; 2015 Jun; 17(6):533-540. PubMed ID: 25678212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.